Dear Traders,
As we can see KALY is retracing, the idea is to find our next entry point.
Have a look at the green circle, that 50 fib level might be our point of interest.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (“GVHD”) .
Kalytera also intends to develop a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a versatile compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera will seek to develop innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.
Website Home: kalytera.co/
News and Insights: kalytera.co/news/
Investors: kalytera.co/investors/
As we can see KALY is retracing, the idea is to find our next entry point.
Have a look at the green circle, that 50 fib level might be our point of interest.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (“GVHD”) .
Kalytera also intends to develop a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a versatile compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera will seek to develop innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.
Website Home: kalytera.co/
News and Insights: kalytera.co/news/
Investors: kalytera.co/investors/
Comment:
As predicted, the price went back to 0.130$ and bounced off, but without a lot of vol, we might see another touch at the 0.5 fib level today, with, hopefully, a bigger bounce off.
I hope to see a lower high, which would confirm more bullish volume.
I hope to see a lower high, which would confirm more bullish volume.
As we can see KALY is retracing a bit after it's 105% run!
My guess, 0.130 is our support point, it's the 0.5 fib level.